A modified 16-amino acid C-terminal fragment of human growth hormone (hGH 177-191) investigated for stimulating lipolysis without elevating IGF-1 or glycemic resistance.
~30 - 60 minutes
Beta-3 Adrenergic Pathway
C78H123N23O23S2
Evaluated via subcutaneous injection and studied in oral formulations in early clinical trials.
Small or observational human data; warrants clinical caution.
Animal (rodent) and in-vitro cellular assays. Does NOT prove human efficacy.
Formal regulatory oversight and verified clinical development phase.
Evidence classification for AOD-9604: Human clinical data is strictly differentiated from non-human animal and in-vitro laboratory assays.
C78H123N23O23S2
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (with cyclic disulfide bridge)
AOD-9604 (Advanced Obesity Drug 9604) was developed to isolate the fat-burning (lipolytic) properties of endogenous human growth hormone from its somatogenic, diabetogenic, and proliferative actions. By cyclizing the 177-191 sequence with an added tyrosine residue at the N-terminus, it stabilizes the conformation required for beta-3 adrenergic and lipolytic pathway activation without binding the primary growth hormone receptor.
Upregulates beta-3 adrenergic receptor signaling and hormone-sensitive lipase (HSL) in adipocytes, stimulating lipolysis and inhibiting lipogenesis without affecting circulating IGF-1, insulin sensitivity, or glucose homeostasis.
Peer-reviewed publications, clinical trials, and preclinical research investigating AOD-9604.
Clinical toxicology trial confirming that the fat-mobilizing peptide fragment AOD-9604 exhibits high tolerability in humans without inducing growth-hormone-like insulin resistance or elevating IGF-1.
Documented literature dosing intervals and published clinical trial protocols.
Frequency: Daily (morning fasted)
“Investigated in morning fasted state to maximize beta-3 adrenergic lipolytic pathways.”
Frequency: Daily (morning fasted)
“Investigated in morning fasted state to maximize beta-3 adrenergic lipolytic pathways.”
Biological delivery routes and standardized laboratory reconstitution principles.
Evaluated via subcutaneous injection and studied in oral formulations in early clinical trials.
Lyophilized peptides must be reconstituted using sterile bacteriostatic water (0.9% benzyl alcohol) and maintained strictly refrigerated between 2°C - 8°C (36°F - 46°F), shielded from light.
View Full Preparation ProtocolCompiled from peer-reviewed biomedical literature, public clinical trial registries, and recognized reference catalog databases.
Pharmacological profiles, receptor targets, and clinical data are verified against primary registries:
Community research topics, peptide nomenclature, and aliases are cross-referenced with public catalogs:
This topic was identified through research of publicly available peptide resources and peer-reviewed literature. Peptide Health Digest provides independent scientific explanations and does not endorse commercial distribution.
